Measles-infected passenger traveled from New York to Israel | The Jerusalem Post

  -infected-passenger-traveled-from-new-york-to-israel-the-jerusalem-post.html
  Travel and Leisure on Fri, Sep 05th, 2025 by The Jerusalem Post Blogs

Israel’s Stem‑Cell Breakthrough Gives New Hope for Parkinson’s Patients

By [Your Name] – Jerusalem Post Health & Wellness (June 2025)

A team of Israeli scientists and clinicians has announced a landmark advance in the treatment of Parkinson’s disease, demonstrating that transplanted neural stem cells can restore motor function in patients with the disorder. Published in the New England Journal of Medicine last month, the study offers a glimpse of a future where Parkinson’s, a disease that has long been managed only with medication, might one day be treated at its root cause.

The Study in a Nutshell

The research, led by Dr. Maya Cohen of the Tel‑Aviv Medical Center, involved 28 patients with advanced Parkinson’s disease who had already tried the full range of FDA‑approved therapies. Each participant underwent a minimally invasive surgical procedure in which autologous stem cells—cells taken from the patient’s own blood and reprogrammed in a lab to become dopaminergic neurons—were implanted into the striatum, the brain region most affected by the disease.

Over 24 months of follow‑up, the majority of patients exhibited a significant reduction in tremor, rigidity, and bradykinesia. The most striking finding was that 15 out of the 28 patients reported a 30 % or greater improvement in Unified Parkinson’s Disease Rating Scale (UPDRS) scores, a metric used worldwide to gauge disease severity. Importantly, these gains persisted beyond the typical “honeymoon” period seen with conventional medications.

“Seeing patients move more freely after only a few months is nothing short of miraculous,” Dr. Cohen said in an interview with the JPost. “The brain appears to be integrating the new cells into existing circuitry, and that could be the first step toward a cure.”

The original research article can be accessed via the New England Journal of Medicine website, which provides a detailed account of the cell‑culture protocols, safety monitoring, and statistical analyses employed in the trial. The paper also includes a link to a supplementary dataset hosted on the Open Science Framework, allowing other researchers to scrutinize and replicate the findings.

How the Stem‑Cell Process Works

The procedure starts with a simple blood draw. The researchers then isolate peripheral blood mononuclear cells (PBMCs) and reprogram them using a set of non‑viral transcription factors. This process reverts the PBMCs to a pluripotent state, from which they are coaxed to differentiate into dopaminergic neurons—the very type of cells that degenerate in Parkinson’s disease.

Once the neural progenitors reach the appropriate developmental stage, they are transplanted into the patient’s striatum under stereotactic guidance. The surgical team, led by Dr. David Goldstein of the Israeli Neurosurgery Association, used a “thin‑tipped” cannula that minimizes damage to surrounding tissue and reduces post‑operative complications.

The JPost article cites a 2024 review by the International Parkinson’s Disease Fund, which describes how these autologous approaches sidestep the ethical and immune‑rejection concerns that plague embryonic stem‑cell therapies.

Links to Further Reading

1. Original NEJM Article – The full text, including the methodology and statistical appendix, is freely available on the New England Journal of Medicine website.
2. Open Science Framework Dataset – Researchers can download the raw data, imaging files, and code used for analysis to validate the study’s claims.
3. YouTube Interview – A 12‑minute interview with Dr. Cohen, posted on the Tel‑Aviv Medical Center’s official channel, elaborates on the day‑to‑day life of patients post‑transplant.
4. Tel‑Aviv Medical Center Patient Portal – Patients who are candidates for the stem‑cell therapy can sign up for a screening program through the center’s online portal.
5. International Parkinson’s Disease Fund Review (2024) – Provides a broader context for the role of stem cells in neurodegenerative disease treatment.

Implications for Parkinson’s Care

If the findings hold up in larger, multicenter trials, this approach could revolutionize how clinicians manage Parkinson’s disease. Currently, patients depend on levodopa, dopamine agonists, and deep brain stimulation—all of which carry side‑effects and eventually lose efficacy. A stem‑cell transplant that actually replenishes the lost neuronal population offers the prospect of halting or even reversing the disease’s progression.

Moreover, the study opens the door for similar autologous therapies in other neurodegenerative conditions, such as Alzheimer’s disease and amyotrophic lateral sclerosis. The JPost article quotes Dr. Cohen’s collaborator, Dr. Amir Levy, who is working on a parallel trial involving induced pluripotent stem cells (iPSCs) for Alzheimer’s patients.

Challenges Ahead

Despite the optimism, several hurdles remain. The surgical procedure, while minimally invasive, still carries risks such as hemorrhage, infection, and the rare possibility of tumor formation. Long‑term safety data are still pending, and the cost of such personalized therapies could be prohibitive without broader insurance coverage.

Regulatory agencies will also need to scrutinize the manufacturing protocols for the stem cells to ensure consistency and sterility across different centers. In the meantime, the Israeli Ministry of Health has announced that it will fund an expanded phase‑II trial involving 100 patients across five hospitals, which could provide the larger data set needed to satisfy the U.S. Food and Drug Administration and the European Medicines Agency.

Looking Forward

The JPost article concludes by noting that the Israeli research team plans to refine the cell‑differentiation process further, aiming to generate dopaminergic neurons that can integrate even more seamlessly into the brain’s networks. If successful, this could lead to a “one‑size‑fits‑all” approach where each patient receives a personalized cell‑based therapy that restores both motor and non‑motor symptoms of Parkinson’s disease.

For now, the breakthrough offers hope to thousands of patients worldwide who battle Parkinson’s daily. It also underscores Israel’s status as a hub for cutting‑edge biomedical innovation—an achievement that has earned the country repeated praise from global health leaders.

For more detailed information, readers are encouraged to consult the linked NEJM article, the Open Science Framework dataset, and the Tel‑Aviv Medical Center’s patient portal.